On the other hand..... Jakafi costs 60,000 USD per year, where as Reme is expected to be around 5 times that, and I am pretty sure the licence agreement included the option for Novartis to be world wide distributer of Reme for GvHD.
So they have their hands in both GvHD pies if they so desire, plus ARDS / COPD. plus who knows what down the line... probably Sepsis.
Novartis are weighing up buying in with Mesoblast and Jakafi sales will suffer but overall Novartis should make a lot more money ..... vs not buying in and they simply loose Jakafi sales and continue not to participate in ARDS for years.
Ann: COVID ARDS Trial Topline 60-Day Results, page-1509
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |